
“High recommendation” yes no need two antibody treatments are used coronavirus applied by the World Health Organization (WHO), as it currently considers them ineffective.
These are monoclonal antibodies. sotrovimab (GSK and Vir Biotechnology) and kazirivimab-imdevimab (“cocktail” of Regeneron and Rocher) that the Agency had previously recommended for use.
A group of international experts from WHO (WHO Guideline Development Group) made a corresponding publication in the British Medical Journal. British Medical Journal (BMJ)).
The new negative recommendation comes after laboratory tests showed the drugs in question are unlikely to work against the new virus. variations coronavirus, in particular Omicron and its subvariants.
Other WHO recommendations
In the same updated guidance, a WHO committee recommends the conditional use of an antiviral drug. remdesivir (Gilead) in patients with severe Covid-19 but not in critically ill patients.
The new recommendation was based on the results of five clinical trials involving 7,643 patients, which showed 13 fewer deaths per 1,000 patients with severe Covid-19 among those taking remdesivir, but 34 more deaths per 1,000 patients with critical Covid-19 .
In addition, the WHO recommends three cures for arthritis (tocilizumab or sarilumab and baricitinib) can now be combined in addition to corticosteroids in patients with severe or critical Covid-19.
Finally, he states against the use of ivermectin and hydroxychloroquine in patients with Covid-19, no matter how seriously ill they are.
Source: RES-IPE
Source: Kathimerini

Lori Barajas is an accomplished journalist, known for her insightful and thought-provoking writing on economy. She currently works as a writer at 247 news reel. With a passion for understanding the economy, Lori’s writing delves deep into the financial issues that matter most, providing readers with a unique perspective on current events.